Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page * ~; T) z4 A9 b" ]. z
; N# Z1 G; I: N( w/ }5 @
/ G' z' U Y5 }' {& ^/ z1 W. `! D
Sub-category:
+ W$ z0 R1 ~) s0 O1 X4 r& l6 LMolecular Targets ! q q+ c% g4 S
( C8 \# d; b% z5 N7 u/ a& |. M
4 f* u8 K, M" ICategory:2 I0 {8 s% @) ~! R _$ _
Tumor Biology
3 \: D' j- ~7 L1 L1 f+ s3 y( j# {) W) y
6 B1 r6 T w/ N/ Q4 P: ?/ D' r/ g% P2 o% Y4 H$ s& C
Meeting:. `- l C- J' M6 k" n9 y j
2011 ASCO Annual Meeting
* }0 a0 ~/ e1 v& F ~+ x, k- r0 ^) b) n, x" D; j: q* s" r; K* b
9 D5 C# }0 Z* s) z/ z
Session Type and Session Title:, h; b. f" Z( e5 _6 z
Poster Discussion Session, Tumor Biology
2 C* V: r. \5 r" g6 z: J) r
9 O8 {& H1 C8 |/ C* U) p0 N8 S- U$ q* g& y# I Q9 Z0 y* Z
Abstract No:
1 l/ B p" P# y1 C+ y10517
; T1 o) w9 I, y. c7 @* J, H: p& y/ N6 @1 T7 \ a1 e0 m
8 m6 z8 E0 n9 h: ^0 z! J! tCitation:
: P. s/ D& ]9 H9 X3 ^1 p" CJ Clin Oncol 29: 2011 (suppl; abstr 10517)
7 V* t' D$ v# x4 [1 V
( g3 }# ?: ]: N( \( B# u* q3 z) ?6 _3 B, O" v4 `
Author(s):
) H+ u# |0 N' A- m0 h7 HJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
b4 D) L) @$ k* t" T4 K, }5 s( o6 c! g! ~) M
5 t" h$ I8 A5 I1 s$ e5 ^$ G, d3 a& i6 w- q0 U: g; p
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
3 j, W% G8 b7 h: H
m1 Q# g% J8 @' W f s! QAbstract Disclosures
! B4 V4 ~. Y2 k p2 z+ }0 e: i7 B2 q, t2 I3 _
Abstract:
: V6 f( |& s# n! j$ {" J/ h4 [3 c8 G3 e' m5 D8 M9 }
. O& O Y1 K: [# @# g' R. E5 S7 e, aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
: X" D7 J2 m1 @/ d# z& E' o0 G6 X
# G& T1 l# ~ \/ r; u! q 1 x ]2 e- s. A0 J) D4 V
|
不知不觉进入第七年。。胸腔积液怎么
中间这几年很顺利也很稳定 这几年都没再关注这个平台。空窗一年半，最近一次复查胸腔
林根教授：2025肺癌治疗新进展全景解
整理者：雨过天晴审核人：鹰版本期“追根溯源”科普直播，聚焦于近期结束的ESMO年会及
76岁的我抗肺癌2年了，5点治疗心得体
作者：丑牛
两年前的九月十五号刚过七十四岁的我被一纸胸片报告引爆了身上一个炸雷！
肿瘤患者预后的“秘密武器”：肌肉的
在人类与癌症漫长而残酷的鏖战中，任何可能改善预后、增加胜算的希望，都被寄予厚望，
4年总生存达到98.4%！ALK阳性早期肺
作者：Tony
一个好消息：又有一批可手术治疗的早期非小细胞肺癌（NSCLC）患者，能够离
# i6 M/ I$ `% D# s
显身卡
